HitGen Inc. 688222.SS Stock
HitGen Inc. Price Chart
HitGen Inc. 688222.SS Financial and Trading Overview
HitGen Inc. stock price | 12.23 CNY |
Previous Close | 17.59 CNY |
Open | 17.52 CNY |
Bid | 18.25 CNY x N/A |
Ask | 18.26 CNY x N/A |
Day's Range | 17.21 - 18.37 CNY |
52 Week Range | 13.26 - 25.14 CNY |
Volume | 10.61M CNY |
Avg. Volume | 9.66M CNY |
Market Cap | 7.31B CNY |
Beta (5Y Monthly) | 0.075428 |
PE Ratio (TTM) | 304.1667 |
EPS (TTM) | 0.08 CNY |
Forward Dividend & Yield | 0.05 (0.27%) |
Ex-Dividend Date | July 11, 2022 |
1y Target Est | 23 CNY |
688222.SS Valuation Measures
Enterprise Value | 6.4B CNY |
Trailing P/E | 304.1667 |
Forward P/E | 114.0625 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 22.378756 |
Price/Book (mrq) | 5.648406 |
Enterprise Value/Revenue | 19.575 |
Enterprise Value/EBITDA | 418.19 |
Trading Information
HitGen Inc. Stock Price History
Beta (5Y Monthly) | 0.075428 |
52-Week Change | 17.58% |
S&P500 52-Week Change | 20.43% |
52 Week High | 25.14 CNY |
52 Week Low | 13.26 CNY |
50-Day Moving Average | 17.76 CNY |
200-Day Moving Average | 16.46 CNY |
688222.SS Share Statistics
Avg. Volume (3 month) | 9.66M CNY |
Avg. Daily Volume (10-Days) | 6.3M CNY |
Shares Outstanding | 400.68M |
Float | 150M |
Short Ratio | N/A |
% Held by Insiders | 68.92% |
% Held by Institutions | 8.11% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0.8333 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 7.02% |
Operating Margin (ttm) | -6.58% |
Gross Margin | 48.59% |
EBITDA Margin | 4.68% |
Management Effectiveness
Return on Assets (ttm) | -0.80% |
Return on Equity (ttm) | 1.77% |
Income Statement
Revenue (ttm) | 326.76M CNY |
Revenue Per Share (ttm) | 0.73 CNY |
Quarterly Revenue Growth (yoy) | -4.00000000000000000000000000000000% |
Gross Profit (ttm) | 329.65M CNY |
EBITDA | 15.29M CNY |
Net Income Avi to Common (ttm) | 22.96M CNY |
Diluted EPS (ttm) | 0.06 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 892.52M CNY |
Total Cash Per Share (mrq) | 2.23 CNY |
Total Debt (mrq) | 237.66M CNY |
Total Debt/Equity (mrq) | 18.07 CNY |
Current Ratio (mrq) | 14.376 |
Book Value Per Share (mrq) | 3.231 |
Cash Flow Statement
Operating Cash Flow (ttm) | 78.32M CNY |
Levered Free Cash Flow (ttm) | -121267712 CNY |
Profile of HitGen Inc.
Country | China |
State | N/A |
City | Chengdu |
Address | Building 6 |
ZIP | 610200 |
Phone | 86 28 8519 7385 |
Website | https://www.hitgen.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 508 |
HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; and HG 381, an immune-oncology agonist for cancer, as well as HGT01 and HGT02, an tumor immunology for cancer. In addition, it offers HGT03, a protein degrader, and HGT04, a transcriptomics for cancer; and HGT05, a kinase inhibitor for liver cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation, and HGC245, a kinase inhibitor for glaucoma. The company's nucleic acid drug pipeline includes HGP2142, an TGF-ß1 specific siRNA drug for liver cancer; HGN001, a nucleic acid drug for specific mutation of cancer target; and HGN002 for Solid tumor. Further, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Additionally, the company focus on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. HitGen Inc. was founded in 2012 and is based in Chengdu, China.
Q&A For HitGen Inc. Stock
What is a current 688222.SS stock price?
HitGen Inc. 688222.SS stock price today per share is 12.23 CNY.
How to purchase HitGen Inc. stock?
You can buy 688222.SS shares on the Shanghai exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for HitGen Inc.?
The stock symbol or ticker of HitGen Inc. is 688222.SS.
Which industry does the HitGen Inc. company belong to?
The HitGen Inc. industry is Biotechnology.
How many shares does HitGen Inc. have in circulation?
The max supply of HitGen Inc. shares is 400.68M.
What is HitGen Inc. Price to Earnings Ratio (PE Ratio)?
HitGen Inc. PE Ratio is 152.87500000 now.
What was HitGen Inc. earnings per share over the trailing 12 months (TTM)?
HitGen Inc. EPS is 0.08 CNY over the trailing 12 months.
Which sector does the HitGen Inc. company belong to?
The HitGen Inc. sector is Healthcare.